Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer

Jianfeng Wang; Yang Liu; Naiwen Zhang; Xuejie Li; Peng Xin; Jianbin Bi; Chuize Kong

doi:10.18632/oncotarget.20147

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer

Jianfeng Wang, Yang Liu, Naiwen Zhang, Xuejie Li, Peng Xin, Jianbin Bi _ and Chuize Kong

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:70874-70882. https://doi.org/10.18632/oncotarget.20147

Metrics: PDF 1323 views | HTML 2395 views | ?

Abstract

Jianfeng Wang1, Yang Liu1, Naiwen Zhang1, Xuejie Li1, Peng Xin1, Jianbin Bi1 and Chuize Kong1

1Department of Urology, The First Hospital of China Medical University, Shenyang 110001, P.R. China

Correspondence to:

Jianbin Bi, email: [email protected]

Chuize Kong, email: [email protected]

Keywords: platelet to lymphocyte ratio, urologic cancer, prognosis, meta-analysis

Received: April 07, 2017 Accepted: May 23, 2017 Published: August 10, 2017

ABSTRACT

The prognostic value of platelet to lymphocyte ratio (PLR) in urologic cancer does not reach a consensus. Herein, we performed the meta-analysis to determine the prognostic role of PLR in patients with urologic cancer. A literature search was performed in the PubMed, Embase, and Web of Science databases. Hazard ratios (HRs) were extracted to estimate the association between PLR and prognosis. A total of 20 articles comprising 6079 patients were included in this study. The pooled results showed that a high PLR was significantly associated with worse prognosis of overall survival (OS) in urologic cancer [HR=1.65, 95% confidence interval (CI) =1.37-1.99, P<0.01]. The result also indicated that an elevated PLR was significantly associated with poor OS in renal cancer (HR=1.88, 95% CI=1.39-2.55, P<0.01). In addition, the significant association between poor OS and elevated PLR in renal cancer was consistent regardless of treatment, cut-off value, sample size and study quality. Our result also indicated that an elevated PLR predicted shorter OS (HR=1.78, 95% CI=1.38-2.30, P<0.01) and cancer-specific survival (HR=2.02, 95% CI=1.24-3.29, P<0.01) in prostate cancer. In conclusion, an elevated PLR was a predictive indicator of poor survival in renal cancer and prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20147

Publication Alerts

Post-Publication Promotion

Research Papers:

Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer

Abstract